School of Translational Medicine, Manchester Academic Health Science Centre, University of Manchester, University Hospital of South Manchester, Manchester M23 9LT, UK.
Trends Microbiol. 2010 May;18(5):195-204. doi: 10.1016/j.tim.2010.02.004. Epub 2010 Mar 6.
This article provides a perspective on the current status of drug therapy for invasive fungal diseases, together with priorities for the future development of novel compounds. Key opportunities for new drugs include production of orally bioavailable agents for the treatment of invasive aspergillosis, invasive candidiasis, cryptococcal meningitis and mucosal and urinary Candida infections. Orally bioavailable agents for the treatment of chronic pulmonary and allergic aspergillosis are also required, as well as new potent drugs against a range of medically important moulds. Antifungal resistance is a problem in certain contexts, but is generally less of a problem than bacterial infections. Earlier and more complete mycological diagnosis and improvements in underlying risk estimation will improve outcomes. The limitations of the current antifungal agents and opportunities for new developments are discussed.
本文提供了对侵袭性真菌病药物治疗现状的观点，并对新型化合物的未来发展提出了重点方向。新药的主要机会包括开发用于治疗侵袭性曲霉病、侵袭性念珠菌病、隐球菌性脑膜炎和黏膜及尿路念珠菌感染的口服生物利用度药物。还需要开发用于治疗慢性肺部和过敏性曲霉病的口服生物利用度药物，以及针对一系列重要医学霉菌的新型强效药物。在某些情况下，抗真菌药物耐药是一个问题，但通常不如细菌感染严重。更早和更完整的真菌学诊断以及对潜在风险评估的改进将改善治疗结果。本文讨论了当前抗真菌药物的局限性和新发展的机会。
